SRRK
SRRK clinical trials: Scholar Rock Holding Corp
Every trial on ClinicalTrials.gov where Scholar Rock Holding Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 9
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
SRRK on the catalyst calendar · SRRK registry changes
- Primary completion Nov 2028Sponsor estimatePhase 2NCT07047144A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyScholar Rock, Inc. · Spinal Muscular AtrophyRecruitingSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 2NCT07435129Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDScholar Rock, Inc. · Facioscapulohumeral Muscular DystrophyRecruitingSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2026Sponsor estimatePhase 3NCT05626855Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabScholar Rock, Inc. · Spinal Muscular AtrophyActive, not recruitingSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06877689EAP of Apitegromab for Patients With Spinal Muscular AtrophyScholar Rock, Inc. · SMANo longer availableSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT07444294A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy AdultsScholar Rock, Inc. · HealthyRecruitingSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2025ActualPhase 2NCT06445075Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseScholar Rock, Inc. · Overweight and ObesityCompletedSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2024ActualPhase 3NCT05156320Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamScholar Rock, Inc. · Spinal Muscular AtrophyCompletedSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2025ActualPhase 1NCT04291079SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)Scholar Rock, Inc. · CancerCompletedSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2021ActualPhase 2NCT03921528An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular AtrophyScholar Rock, Inc. · Spinal Muscular AtrophyCompletedSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2026ActualNo phase registeredNCT06419322Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy...University of Oxford · Spinal Muscular AtrophyCompletedBHVNCollaboratorSRRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner